logo

Foghorn Therapeutics Inc. (FHTX)



Trade FHTX now with
  Date
  Headline
3/17/2022 9:25:20 AM Wedbush Is Lowering Foghorn Therapeutics Inc. (FHTX) FY 22 Estimate To -1.28 From -1.03
3/17/2022 9:25:06 AM Wedbush Is Lowering Foghorn Therapeutics Inc. (FHTX) Q4 22 Estimate To -0.37 From -0.30
3/17/2022 9:24:50 AM Wedbush Is Lowering Foghorn Therapeutics Inc. (FHTX) Q3 22 Estimate To -0.35 From -0.29
3/17/2022 9:24:36 AM Wedbush Is Cutting Foghorn Therapeutics Inc. (FHTX) Q2 22 Estimate To -0.29 From -0.23
3/17/2022 9:24:24 AM Wedbush Is Cutting Foghorn Therapeutics Inc. (FHTX) Q1 22 Estimate To -0.27 From -0.21
3/17/2022 9:23:56 AM Wedbush Reiterates Foghorn Therapeutics Inc. (FHTX) At Outperform With $32 Price Target
12/13/2021 6:01:47 AM Lilly And Foghorn Announce Strategic Collaboration For Novel Oncology Targets
8/23/2021 7:20:32 AM Foghorn Therapeutics Doses First Patient In First-in-Human Clinical Trial Of FHD-609
5/19/2021 9:45:37 AM Invaio Sciences Announces Agreement With Fundecitrus In Brazil To Combat Against Citrus Greening